Amarin Seeks Injunction Blocking FDA's Off-Label Muzzle
By Joe Van Acker ( May 26, 2015, 2:19 PM EDT) -- Amarin Pharma Inc. and doctors claiming the U.S. Food and Drug Administration has violated their First Amendment rights by restricting "truthful and non-misleading" statements about off-label uses for cardiovascular drug Vascepa asked a New York federal court on Friday to block the agency's enforcement....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.